echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Oncolytic virus based on synthetic biology technology applied for clinical medicine in China, Mai Meng broke the news

    Oncolytic virus based on synthetic biology technology applied for clinical medicine in China, Mai Meng broke the news

    • Last Update: 2021-08-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recent popular reports from Yimaike ★From questioned to full-fledged: CD47 track competition flourishesYimai violently broke the news ★Pharmaceutical financingWest Lake Biomedicine has received another 100 million yuan in financing, funded by Sequoia China, Stow Capital, Chende Capital and other veterans Shareholders make additional investment, click on the picture, and sign up now July 16, 2021/eMedClub News/--The Center for Drug Evaluation (CDE) of the National Medical Products Administration showed that the "SynOV1.
    1 gland" declared by Beijing Hesheng Gene Technology Co.
    , Ltd.
    "Virus injection" clinical trial application was accepted (acceptance number: CXSL2101198)
    .

    ▲ Image source: CDESynOV1.
    1 is the first gene therapy product developed by domestic original synthetic biotechnology.
    It is an oncolytic virus drug that intelligently targets primary liver cancer (HCC), which can greatly improve the targeting and treatment of liver cancer.
    Effectiveness and safety
    .

    On November 27, 2020, Synbiotics announced that SynOV1.
    1 has obtained the US FDA clinical trial approval for the treatment of alpha-fetoprotein (AFP)-positive solid tumors including advanced liver cancer
    .

    Recommended reading: Obtained FDA clinical approval! The world's first oncolytic virus based on synthetic biology technology has entered the clinical stageYimai Meng broke the news that Syngene was established in 2014.
    It is an innovative biotechnology company that independently designs and researches and develops gene and cell therapy based on synthetic biology technology.
    Drugs to meet clinical needs
    .

    With the development of biotechnology and information technology, synthetic biology can use biological elements to construct genetic circuit modifications and program living organisms
    .

    Redesigning gene circuits, biological modules and synthetic pathways can be used to solve major disease problems
    .

    Biomarkers and synthetic gene circuits can regulate the dosage, timing and positioning of gene expression and therapeutic activities, and provide new intervention methods for cancers and other incurable or difficult-to-treat diseases
    .

    Dr.
    Xie Zhen, the founder and chief scientist of Synbiotics, is an associate professor in the Department of Automation of Tsinghua University.
    Since 2006, Dr.
    Xie Zhen has been engaged in synbiotics-related research at Harvard University and MIT, laying a solid foundation for the multiple technology platforms of Syngenes.
    Basis
    .

    Dr.
    Xie Zhen returned to China in 2012 and founded Synbiotic Gene in 2014
    .

    Dr.
    Bin Chen, CEO of Synbiotics, has worked in the field of biomedicine for many years.
    He has worked in the drug R&D departments of many well-known multinational pharmaceutical companies such as Amgen, Johnson & Johnson, and Bayer.
    He has 15 years of pre-clinical and biologics drug research and development.
    clinical development experience, to get involved in the therapeutic areas including immunization, cancer, cardiovascular and metabolism
    .

    Synbiotics has attached great importance to basic scientific research and continued to invest for many years.
    The company has successfully transformed the technology of regulating biological drugs by synthetic gene circuits into a rich R&D pipeline, and transformed oncolytic adenoviruses through synthetic biology technology
    .

    The product pipeline launched by Synbiotics mainly targets liver cancer, gastric cancer, pancreatic cancer, and other solid tumors that have a high incidence in China and the Asia-Pacific region
    .

    Image source: Synthetic Gene's official website The core of synthetic biology is to use engineering thinking to construct target man-made complex biological systems that perform specific biological functions
    .

    The pathogenesis of major diseases such as tumors is complex and heterogeneous.
    Complex biological systems regulated by logical gene circuits have a higher ability to solve complex system problems
    .

    At present, synthetic biology is showing its application potential in various aspects such as biological design, medical health, industrial chemicals, biofuels, food and beverages
    .

    Design·Build·Test·Learning Cycle (DBTL) is the core research and development model of synthetic biology drug development, rapid development and screening of high-efficiency drug products
    .

    Synbiotics has adopted the DBTL model to develop a variety of oncolytic viruses and cell therapy products regulated by gene circuits
    .

    Image source: Synbiotics' official website Reference materials: 1.
    CDE 2.
    Synbiotics' official website Medical Mark has always been committed to the cutting-edge technology, industry trends, industry insights and other original news reports of bio-innovative drugs.
    The full-media high-end matrix users have reached 160,000+, including industrial Users accounted for more than 50%, about 30% of scientific research and clinical users, and more than 5% of users of investment institutions
    .

    In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.